Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 23.76 USD 3.62% Market Closed
Market Cap: 504.2m USD

Wall Street
Price Targets

LYEL Price Targets Summary
Lyell Immunopharma Inc

Wall Street analysts forecast LYEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYEL is 39.27 USD with a low forecast of 32.32 USD and a high forecast of 47.25 USD.

Lowest
Price Target
32.32 USD
36% Upside
Average
Price Target
39.27 USD
65% Upside
Highest
Price Target
47.25 USD
99% Upside
Lyell Immunopharma Inc Competitors:
Price Targets
TNG
Transgene SA
57% Upside
TECX
AVROBIO Inc
333% Upside
068270
Celltrion Inc
13% Upside
IDYA
IDEAYA Biosciences Inc
41% Upside
ARGX
argenx SE
25% Upside
MDXH
MDxHealth SA
87% Upside
APLS
Apellis Pharmaceuticals Inc
81% Upside
IMTX
Immatics NV
95% Upside

Revenue
Forecast

Revenue Estimate
Lyell Immunopharma Inc

For the last 4 years the compound annual growth rate for Lyell Immunopharma Inc's revenue is -70%. The projected CAGR for the next 4 years is 423%.

-70%
Past Growth
423%
Estimated Growth
Estimates Accuracy
62%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Lyell Immunopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Lyell Immunopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYEL's stock price target?
Price Target
39.27 USD

According to Wall Street analysts, the average 1-year price target for LYEL is 39.27 USD with a low forecast of 32.32 USD and a high forecast of 47.25 USD.

What is Lyell Immunopharma Inc's Revenue forecast?
Projected CAGR
423%

For the last 4 years the compound annual growth rate for Lyell Immunopharma Inc's revenue is -70%. The projected CAGR for the next 4 years is 423%.

Back to Top